- Alexion Pharmaceuticals has closed a private placement of $10million in stock to BB Biotech; Xcyte Therapies, a private biopharmaceutical company formed from the merger of CDR Therapeutics and CellGenEx, has completed a $4.1 million Series B financing; Genzyme Molecular Oncology has raised $20 million in a private placement of 6% convertible debentures due in 2002; Neocrin Co has raised $16.5 million in private equity financing; Prizm Pharmaceuticals has completed a $4.2 million private round of financing; and Pharma Vision 2000 is to purchase $51.25 million of Tularik Preferred Stock in a private placement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze